Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study by Crandall, Carolyn et al.
Open Access
Available online http://breast-cancer-research.com/content/7/6/R922
R922
Vol 7 No 6 Research article
Positive association between mammographic breast density and 
bone mineral density in the Postmenopausal Estrogen/Progestin 
Interventions Study
Carolyn Crandall1, Shana Palla2, Beth A Reboussin2, Giske Ursin3,4 and Gail A Greendale5
1Division of General Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA, USA
2Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA
3Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
4Department of Nutrition, University of Oslo, Oslo, Norway
5Department of Geriatrics, David Geffen School of Medicine at University of California, Los Angeles, CA, USA
Corresponding author: Carolyn Crandall, ccrandall@mednet.ucla.edu
Received: 4 Jun 2005 Revisions requested: 3 Aug 2005 Revisions received: 25 Aug 2005 Accepted: 6 Sep 2005 Published: 22 Sep 2005
Breast Cancer Research 2005, 7:R922-R928 (DOI 10.1186/bcr1327)
This article is online at: http://breast-cancer-research.com/content/7/6/R922
© 2005 Crandall et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Mammographic breast density is a strong
independent risk factor for breast cancer. We hypothesized that
demonstration of an association between mammographic
breast density and bone mineral density (BMD) would suggest
a unifying underlying mechanism influencing both breast density
and BMD.
Methods In a cross-sectional analysis of baseline data from the
Postmenopausal Estrogen/Progestin Interventions Study
(PEPI), participants were aged 45 to 64 years and were at least
1 year postmenopausal. Mammographic breast density
(percentage of the breast composed of dense tissue), the
outcome, was assessed with a computer-assisted percentage-
density method. BMD, the primary predictor, was measured with
dual-energy X-ray absorptiometry. Women quitting menopausal
hormone therapy to join PEPI were designated recent hormone
users.
Results The mean age of the 594 women was 56 years. The
average time since menopause was 5.6 years. After adjustment
for age, body mass index, and cigarette smoking, in women who
were not recent hormone users before trial enrollment (n = 415),
mammographic density was positively associated with total hip
(P = 0.04) and lumbar (P = 0.08) BMD. Mammographic density
of recent hormone users (n = 171) was not significantly related
to either total hip (P = 0.51) or lumbar (P = 0.44) BMD. In
participants who were not recent hormone users,
mammographic density was 4% greater in the highest quartile
of total hip BMD than in the lowest. In participants who were not
recent hormone users, mammographic density was 5% greater
in the highest quartile of lumbar spine BMD than in the lowest.
Conclusion Mammographic density and BMD are positively
associated in women who have not recently used
postmenopausal hormones. A unifying biological mechanism
may link mammographic density and BMD. Recent exogenous
postmenopausal hormone use may obscure the association
between mammographic density and BMD by having a
persistent effect on breast tissue.
Introduction
Mammographic density is a stronger risk factor for breast can-
cer than almost all other known breast cancer risk factors [1-
5]. Bone mineral density (BMD) is another predictor of breast
cancer risk in older women. Elderly women with high BMD
have a greater risk of breast cancer than women with low BMD
[6-10].
An underlying common pathway involving endogenous estro-
gen exposure or responsiveness to estrogen may link higher
breast density, increased breast cancer risk, and greater BMD.
Previous observations support this theory: markers of
increased lifetime estrogen exposure are associated with
higher breast cancer risk [11], higher BMD [12-14], and
higher mammographic breast density [15,16]. However, it has
not been established whether higher mammographic density
BMD = bone mineral density; PEPI-MDS = Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study; PEPI = Postmenopau-
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is associated with higher BMD [17,18]. If mammographic den-
sity were associated with BMD, the notion of a common bio-
logical mechanism linking breast density, breast cancer risk,
and BMD would be further supported.
To test whether BMD is an independent determinant of mam-
mographic density in menopausal women, we examined base-
line data from participants in the Postmenopausal Estrogen/
Progestins Intervention Mammographic Density Study (PEPI-
MDS), a substudy of the Postmenopausal Estrogen/Progestin
Interventions Study (PEPI).
Materials and methods
PEPI
PEPI, designed to determine the effects of postmenopausal
hormone therapy on cardiovascular risk factors and BMD in
menopausal women, enrolled 875 menopausal women aged
45 to 64 years at seven clinical centers between 1989 and
1991. The eligibility criteria and study design have been
reported in detail previously [19]. In brief, menopause was
defined as the last menses having occurred at least 12 months
ago. Women with any major contraindication for the use of
estrogen or progestin treatment (for example breast cancer),
or with any cancer other than basal cell skin cancer within the
previous 5 years, were excluded. Additional exclusion criteria
were the following: hysterectomy less than 2 months before
screening, bilateral oophorectomy before age 44 years or
more than 10 years previously, or serum levels of follicle-stim-
ulating hormone less than 40 mIU/ml. Women who were using
menopausal hormone therapy at the time of recruitment could
join the trial if they stopped their privately prescribed hormone
therapy at least 2 months before the first screening visit. For
the present analysis, women who stopped their privately pre-
scribed hormones to join PEPI are termed 'recent postmeno-
pausal hormone users'.
Before recruitment, each clinic principal investigator obtained
institutional review board approval for the informed consent
information that was provided to study participants. All partic-
ipants provided signed consent.
PEPI-MDS
As part of the parent PEPI study, all enrolled women under-
went mammography at baseline. PEPI-MDS, initiated after the
parent PEPI, is intended to elucidate several hormonal,
genetic, and lifestyle determinants of mammographic breast
density in all participants in PEPI who had technically ade-
quate mammograms.
Measurements
We used baseline (before randomization) data from PEPI to
determine the relationship between BMD and mammographic
breast density. BMD was measured in duplicate with a
Hologic QDR 1000 densitometer [20]. The in vivo coefficients
of variation were 1.2% or less for measures of the hip and
spine.
PEPI-MDS used mammograms obtained in the original PEPI to
quantify mammographic density, the percentage of the breast
composed of dense tissue, by using digitized mammograms,
described in detail previously [21,22]. In brief, pre-randomiza-
tion conventional craniocaudal mammograms performed
between 1989 and 1994 during the original PEPI were
retrieved from the seven participating PEPI clinical sites. Mam-
mograms were scanned at a resolution of 150 pixels per inch
with a Cobrascan CX-312T scanner (Radiographic Digital
Imaging, Inc., Compton, CA) and Adobe Photoshop software
(Adobe Systems, Inc., San Jose, CA) with ScanWizard 3.0.9,
a specially designed program (Microtek International, Inc.,
Carson, CA). Breast tissue was outlined on a digitized mam-
mogram image, and artefacts (for example pectoralis muscle)
were excluded. Next, the reader established for each mammo-
gram a 'yes/no' threshold above which breast tissue was
defined as dense, and below which breast tissue was defined
as not dense. Yellow tint was applied to areas of the image
that were above this threshold; that is, dense. The software
calculated percentage density as the ratio of the dense tinted
area to the total area of the breast. The test–retest reliability for
breast density, percentage breast density, and total breast
area was high: intra-class correlation coefficients were more
than 0.95 for mammograms that were rated not difficult to read
or slightly difficult to read, and 0.91 to 0.95 for mammograms
that were difficult or very difficult to read [22].
Covariates considered in this analysis were those related to
mammographic density, BMD, or both [15,20,22-32], and
include baseline, age, smoking history, use of postmenopausal
hormone therapy before PEPI, and physical activity level (lei-
sure, home, occupational), which were determined with stand-
ardized questionnaires [19]. Weight and height were
measured, and body mass index (kg/m2) was calculated, at the
screening and baseline visits, in accordance with a standard-
ized algorithm [33].
Statistical analysis
Generalized linear models were created with baseline per-
centage mammographic density as the outcome variable.
Total hip BMD and baseline lumbar BMD were the two primary
exposure variables. Covariates were chosen a priori on the
basis of previous publications [15,20,22-32]. Models were
adjusted for body mass index (continuous), age (continuous),
and current cigarette smoking (yes/no). Because the relation
between endogenous sex steroid hormones and mammo-
graphic density could be obscured by the effects of recent
hormone use [22], analyses were stratified by whether women
were recent hormone therapy users.
Although this study relies on the continuous BMD exposure
variable for its primary analysis, we calculated adjusted meanAvailable online http://breast-cancer-research.com/content/7/6/R922
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percentage mammographic density in each quartile of lumbar
spine BMD and total hip BMD as a means of illustrating the
magnitude of the association between mammographic density
and BMD among women who had not recently used postmen-
opausal hormones. All analyses were performed with Stata
Table 1
Demographic and behavioral characteristics of PEPI-MDS participants by recent use of menopausal hormones
Characteristic Quit hormones to join PEPI (n = 173)a Did not quit hormones to join PEPI 
(n = 143)
Never used hormone therapy (n = 274)b
Mean (SD) Frequency (%) Pc Mean (SD) Frequency (%) Pd Mean (SD) Frequency (%) Pe
Age, years 55.9 (4.1) 0.27 56.4 (4.8) 0.31 55.9 (4.2) 0.84
Years since 
menopause
5.6 (2.5) 0.26 6.0 (2.6) 0.15 5.5 (2.8) 0.86
Body mass index, 
kg/m2
25.2 (4.1) 0.003 26.7 (4.5) 0.66 26.5 (4.7) 0.002
Months since 
menopausal 
hormone usef
6.5 (12.0) <0.001 47.8 (60.0) N/A N/A N/A
Alcohol use, g/
day
6.2 (9.9) 0.99 6.1 (12.1) 0.67 6.7 (14.1) 0.66
Percentage 
mammographic 
density
0.28 (0.18) 0.01 0.23 (0.17) 0.68 0.23 (0.18) 0.01
Total hip bone 
mineral density, 
g/cm2
0.866 (0.128) 0.82 0.863 (0.127) 0.71 0.858 (0.120) 0.51
Lumbar bone 
mineral density, 
g/cm2
0.997 (0.164) 0.01 0.952 (0.154) 0.54 0.962 (0.154) 0.02
Non-white, 
number (%)
13 (7.5) 0.007 25 (17.5) 0.10 32 (11.7) 0.15
Smoking
Current 10 (5.8) 0.01 24 (16.1) 0.74 43 (15.7) 0.006
Former 73 (42.2) 55 (38.5) 96 (35.0)
Never 90 (52.0) 65 (45.5) 135 (49.3)
Physical activity level, number (%)g
Low (score < 
1.5)
47 (27.1) 0.04 58 (40.6) 0.31 91 (33.2) 0.40
Medium 
(score = 
1.5)
64 (37.0) 42 (29.4) 95 (34.7)
High (score > 
1.5)
62 (35.8) 43 (30.1) 88 (32.1)
Of the 594 women who had adequate mammographic density measurements, 4 did not have complete information on other variables and are not 
included in the analyses. The table displays information regarding the remaining 590 women.
aWomen who were using menopausal hormone therapy at the time of recruitment could join the trial if they stopped their privately prescribed 
hormone therapy at least 2 months before the first screening visit. A total of 317 participants answered the question regarding whether they quit 
menopausal hormone therapy to join PEPI.
bThis column also includes women who did not remember whether they had used hormone therapy.
cP value comparing the characteristic in the participants who quit hormones to join PEPI with the participants who did not quit hormones to join 
PEPI.
dP value comparing the characteristic in the participants who did not quit hormones to join PEPI with the participants who never used hormone 
therapy.
eP value comparing the characteristic in the participants who never used hormone therapy with the participants who quit hormones to join PEPI.
fNumber of months since menopausal hormone therapy use in women who had used hormones previously. In the overall sample, the mean 
duration since last use of hormone therapy was 4.1 months (range 3.1 to 5.1 months).
gLeisure and home physical activity self-rated by participants: inactive (1), light (2), moderate (3).
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Version 7 (Stata Corporation, College Station, TX). All statisti-
cal tests were two-sided.
Results
Of the 875 women in the original PEPI, 594 women had
retrievable and technically adequate mammograms and thus
comprised the PEPI-MDS sample. All 594 women in the PEPI-
MDS underwent BMD measurement as part of the original
PEPI. Because of missing covariate information, four women in
PEPI-MDS were not included in the current analysis, leaving
an analytic sample of 590 women. Characteristics of the PEPI
mammographic density participants are displayed in Table 1,
classified by previous menopausal hormone therapy use.
Mean age of the 590 women comprising the analytic sample
was 56 years. On average, women had experienced meno-
pause 5.6 years before enrollment in PEPI; 88% were Cauca-
sian and few (13%) were current smokers. Recent users of
postmenopausal hormones numbered 173 (29%); that is, they
discontinued previously prescribed hormones to join PEPI.
The mean duration since last use of hormone therapy at base-
line was 4.1 months (range 3.1 to 5.1). Among the subset of
women who stopped hormone therapy to join PEPI (that is,
recent users), the mean duration since last use of hormone
therapy was 6.5 months.
The multiple regression analyses in Table 2 show that, in
women who were not recently exposed to postmenopausal
hormone therapy, mammographic density was positively asso-
ciated with both hip (P = 0.04) and lumbar (P = 0.08) BMD.
In contrast, in the stratum of women who were recent post-
menopausal hormone users, mammographic density was not
significantly related to either hip (P = 0.51) or lumbar (P =
0.44) BMD.
To gauge the magnitude of the relation between percentage
mammographic density and BMD, we calculated the adjusted
mean percentage mammographic density by quartile of BMD
(Figure 1). The increment in mammographic density between
the lowest and the highest quartiles of spine BMD was 5%
(Fig. 1a). The pattern of change in mammographic density
across the quartiles of hip BMD (Fig. 1b) was similar to that of
spine BMD, with an increment of 4% between the lowest and
highest quartile of BMD.
Discussion
In PEPI-MDS participants who had not recently used post-
menopausal hormones, mammographic density was positively
associated with total hip and lumbar spine BMD. By contrast,
mammographic density was not associated with BMD in
recent users of menopausal hormone therapy. Thus, exoge-
nous postmenopausal hormone use (a mean of 6 to 7 months
before baseline measurement) seems to obscure the associa-
tion between mammographic breast density and BMD, pre-
sumably owing to a residual effect of recent hormone therapy
use on breast density.
Findings of two previous publications are available for compar-
ison with our findings. A cross-sectional population-based
analysis of postmenopausal women found no significant asso-
ciation between BMD and breast density after adjustment for
body mass index [17]. The previous study was not able to
account for the timing of postmenopausal hormone therapy
use in relation to mammographic density and BMD
measurement, which had a major interactive effect in our
study. Thus, the previous study's null finding might be due to a
lack of stratification by current or previous hormone therapy
use.
The second study found no relation between BMD and mam-
mographic density after separately examining postmenopausal
women using, and not using, hormone therapy [18]. However,
that study assessed previous hormone therapy differently from
our study in that they did not separately assess recent hor-
mone users. Rather, the previous study classified recent users
as nonusers. If, as our findings suggest, recent hormone use
has residual effects that may obscure the association between
mammographic density and BMD, the study's lack of separate
analysis according to recent hormone use could be a reason
why it did not find an association between mammographic
density and BMD even in the nonusers. In addition, because
the other study did not measure BMD in all women who had
mammograms, it is possible that women who did receive BMD
testing were different from those who did not receive BMD
Table 2
Association between mammographic breast density and bone mineral density stratified by recent hormone therapy use
Sample Total hip BMD (g/cm2) Lumbar spine BMD (g/cm2)
β, mean (SEM) P β, mean (SEM) P
Not recent hormone users (n = 417) 0.156 (0.076) 0.04 0.099 (0.056) 0.08
Recent hormone users (n = 173) -0.073 (0.110) 0.51 -0.065 (0.083) 0.44
Mammographic density was expressed as the percentage of the breast composed of dense tissue by using a semi-quantitative method [21]. The 
outcome of linear regression models was percentage mammographic density. Models were adjusted for body mass index (kg/m2, continuous), 
age (continuous), and current smoker (versus former or never smoker). Recent hormone users were defined as women who had stopped taking 
hormone therapy for PEPI.
BMD, bone mineral density; PEPI, Postmenopausal Estrogen/Progestin Interventions Study.Available online http://breast-cancer-research.com/content/7/6/R922
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testing in certain key characteristics that obscured the associ-
ation between mammographic density and BMD.
Despite the paucity of previously published studies directly
examining a link between breast density and BMD, several
lines of research are consistent with our findings: BMD is
associated with breast cancer risk [6,7] and with indicators of
endogenous estrogen exposure [13,34], and mammographic
breast density is also associated with breast cancer risk [1-4]
and with indicators of exposure to endogenous estrogen
[15,16,35].
In addition to biological plausibility as described above, our
results are congruent with the known effects of pharmacologic
agents, such as hormone therapy or estrogen antagonists. For
example, in the original PEPI, administration of combination
estrogen–progestin hormone therapy to menopausal women
increased BMD by between 2% and 5% over 36 months [20]
and also increased mammographic breast density by between
3% and 5% over 12 months [22,36]. The degree of increase
in estrone level [37,38] and estradiol level [38] predicts the
increase in mammographic density with administration of
exogenous estrogen and progestin hormone.
Although this study was not designed to measure hormonal
markers, we can postulate that other hormonal factors besides
estrogen may jointly affect BMD and mammographic density
and explain their association in this analysis. Evidence from a
randomized trial would arouse suspicion that progesterone
might be an important mediator of mammographic density.
PEPI found that mammographic density was increased only
with the administration of combined estrogen and progestin,
not estrogen alone, compared with placebo [22]. Although
one study found progesterone level to be unrelated to mam-
mographic breast density [39], and one study found no asso-
ciation between endogenous progesterone levels and BMD
[40], a possible role for endogenous progesterone in deter-
mining both mammographic density and BMD warrants inves-
tigation. Alternatively, the mechanism underlying the
association between mammographic density and BMD might
involve other steroid sex hormones.
Whether moderated by estrogen alone or with other factors,
the association we report between BMD and mammographic
breast density suggests that there is a unifying biological
mechanism behind BMD, mammographic density, and breast
cancer risk. Moreover, we witnessed a 4 to 5% difference in
mammographic density in the highest compared with the low-
est quartile of BMD. This suggests an effect of biological con-
sequence: relative risk of breast cancer increases by between
1.5% and 2% for each 1% increment in endogenous breast
density [4,5]. Breast density is a strong risk factor for breast
cancer, and its determinants are currently poorly understood.
Linking breast density with other better-known biological out-
comes, such as BMD, may be a step towards our understand-
ing of what determines this strong risk factor for breast cancer.
Strengths of our study include large sample size, the ability to
control for several potential confounders, contemporaneous
ascertainment of mammograms and bone density tests on all
participants, and detailed information about previous post-
menopausal hormone exposure. However, our cross-sectional
study design does not permit attribution of causation. The
study design did not allow us to determine the association
Figure 1
Association between mammographic density and bone density in  women who were not recent hormone therapy users Association between mammographic density and bone density in 
women who were not recent hormone therapy users. (a) Mammo-
graphic density by quartile of lumbar spine bone mineral density (BMD) 
in  participants who were not recent hormone therapy users. Recent 
hormone users  were defined as women who stopped taking hormone 
therapy to join the  Postmenopausal Estrogen/Progestin Interventions 
Study (PEPI). Women who were  not recent hormone therapy users 
were women who did not stop taking hormone  therapy to join PEPI. (b) 
Mammographic density by quartile of total  hip BMD in participants who 
were not recent hormone therapy users.Breast Cancer Research    Vol 7 No 6    Crandall et al.
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between BMD or breast density and breast cancer. It is
unknown whether our findings apply to women in other age
groups (elderly, premenopausal) or ethnic groups (our popula-
tion was 70% Caucasian).
Conclusion
In conclusion, mammographic density was not associated with
BMD in recent users of postmenopausal hormone therapy,
which is consistent with a residual effect of hormone therapy
on mammographic density. In women who were not recent
users of postmenopausal hormones, mammographic density
was positively associated with BMD, suggesting a unifying
biological mechanism linking BMD and mammographic
density.
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